Evidence map›Paper›PMID 30055632›Full record

ReviewRetrovirology2018

HIV-1 cell-to-cell transmission and broadly neutralizing antibodies.

Jérémy Dufloo, Timothée Bruel, Olivier Schwartz

Open access · goldAbstract readReview
In one paragraph

Review in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Role of Monocyte/Macrophages in the Pathogenesis of NeuroHIV.Results and problems in cell differentiation · 2024
    Review
  12. Article
  13. Review
  14. Riding apoptotic bodies for cell-cell transmission by African swine fever virus.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Review
  16. Antigen Presenting Cell-Mediated HIV-1Medical research archives · 2023
    Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Jérémy DuflooVirus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
Timothée BruelVirus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
Olivier SchwartzVirus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France. schwartz@pasteur.fr.
Centre National de la Recherche Scientifique · FRDepartment of Virology · FRInstitut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 spreads through contacts between infected and target cells. Polarized viral budding at the contact site forms the virological synapse. Additional cellular processes, such as nanotubes, filopodia, virus accumulation in endocytic or phagocytic compartments promote efficient viral propagation. Cell-to-cell transmission allows immune evasion and likely contributes to HIV-1 spread in vivo. Anti-HIV-1 broadly neutralizing antibodies (bNAbs) defeat the majority of circulating viral strains by binding to the viral envelope glycoprotein (Env). Several bNAbs have entered clinical evaluation during the last years. It is thus important to understand their mechanism of action and to determine how they interact with infected cells. In experimental models, HIV-1 cell-to-cell transmission is sensitive to neutralization, but the effect of antibodies is often less marked than during cell-free infection. This may be due to differences in the conformation or accessibility of Env at the surface of virions and cells. In this review, we summarize the current knowledge on HIV-1 cell-to-cell transmission and discuss the role of bNAbs during this process.

Indexed as

AnimalsAntibodies, NeutralizingCD4-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansImmune EvasionMacrophagesModels, BiologicalSynapsesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesbNAbsCell-to-cell transmissionHIV-1Neutralization

Identifiers

PMID30055632
PMCPMC6064125
OpenAlexW2883776741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.